Opportunity Information: Apply for RFA CA 15 023
Apply for RFA CA 15 023
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Proteogenomic Data Analysis Centers for Clinical Proteomic Tumor Analysis Consortium (U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.396,.
- This funding opportunity was created on Nov 02, 2015 and posted on Nov 02, 2015.
- Applicants must submit their applications by Jan 27, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $675,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Proteogenomic Data Analysis Centers for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (U24) funding opportunity, RFA-CA-15-023, is a National Cancer Institute (NCI) cooperative agreement designed to expand and strengthen national efforts in cancer proteomics and proteogenomics. Its core purpose is to capitalize on newer advances in large-scale protein and genomic measurement technologies and to speed up cancer research by building, analyzing, and widely sharing high-value datasets and analytical resources with the broader scientific community. In practice, this program is meant to help researchers better understand how changes in cancer genomes translate into changes in the cancer proteome, and how those protein-level consequences shape tumor biology, behavior, and potential treatment vulnerabilities.
A central theme of the opportunity is the establishment and support of specialized data analysis centers that can handle complex, multi-omic cancer data at scale. These centers are expected to focus on multiple cancer types and dig into the biological complexity of tumors by integrating proteomic measurements (proteins and related features) with genomic abnormalities (such as DNA-level alterations). The intent is not only to generate insights within individual projects, but also to produce reusable resources, analytical methods, and curated results that other investigators can apply to their own studies. By structuring the awards as U24 cooperative agreements, the FOA signals that awardees will work in close coordination with NCI and with the broader CPTAC network, reflecting a collaborative, consortium-based model rather than isolated, investigator-driven projects.
The FOA also highlights a translational goal: using proteomic and proteogenomic strategies to address clinically relevant questions. One explicit example given is improving the ability to predict which treatments are likely to work for a given patient’s tumor. This points toward analyses that connect molecular profiles to therapeutic response, resistance mechanisms, and clinically meaningful tumor subtypes. The larger promise is that protein-level data, when combined with genomic information, can reveal functional pathway activation and actionable biology that may not be obvious from DNA or RNA data alone, thereby improving interpretation of tumor mechanisms and potentially informing precision oncology decisions.
From an administrative and eligibility standpoint, the opportunity is categorized as a discretionary grant using the cooperative agreement funding instrument, under the broad activity areas of education and health. It is associated with CFDA numbers 93.393, 93.394, and 93.396. The eligible applicant pool is wide and includes state, county, and local governments; tribal governments and tribal organizations; public housing authorities; independent school districts; public and private institutions of higher education; nonprofits (including both 501(c)(3) and non-501(c)(3) organizations); for-profit organizations (including small businesses and other for-profits); and other entities as allowed under the announcement’s additional eligibility guidance. The sponsoring agency is listed as HHS-NIH (NCI).
Key timing and funding details show this was posted and created on November 2, 2015, with an application closing date of January 27, 2016. The FOA anticipated making about four awards, with an award ceiling of $675,000. Overall, the opportunity is best understood as an infrastructure-and-analysis focused component of CPTAC, aimed at building robust proteogenomic analytical capacity, producing standardized and shareable research outputs, and accelerating community access to data and tools that can deepen understanding of cancer biology while also supporting clinically oriented discovery.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Proteogenomic Data Analysis Centers for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (U24)" and is associated with FOA number RFA-CA-15-023.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Cancer Institute (NCI) within HHS-NIH.
What type of funding mechanism is being used?
This is a U24 cooperative agreement. That means it is structured as a cooperative agreement rather than a traditional research project grant, with awardees expected to work in close coordination with NCI and the broader CPTAC network.
What is the main purpose of this program?
The core purpose is to expand and strengthen national efforts in cancer proteomics and proteogenomics by taking advantage of advances in large-scale protein and genomic measurement technologies. The program is intended to speed up cancer research by building, analyzing, and widely sharing high-value datasets and analytical resources with the broader scientific community.
What is CPTAC in this context?
CPTAC refers to the Clinical Proteomic Tumor Analysis Consortium. In this opportunity, the program supports a consortium-based model where funded centers contribute analysis capacity, resources, and shareable outputs that align with CPTAC goals.
What is meant by "proteogenomics" here?
Proteogenomics here refers to integrating proteomic measurements (protein-level data and related features) with genomic abnormalities (such as DNA-level alterations) to better understand tumor biology and the functional consequences of genomic changes.
What kinds of centers is the FOA aiming to establish or support?
The FOA emphasizes establishing and supporting specialized proteogenomic data analysis centers that can handle complex, multi-omic cancer data at scale, integrate proteomic and genomic information, and produce widely usable datasets, methods, and curated analytical results.
What scientific focus is expected for these data analysis centers?
Centers are expected to analyze complex, multi-omic tumor datasets by integrating proteomic measurements with genomic abnormalities, with an emphasis on interpreting how genomic changes translate into protein-level consequences and how those consequences influence tumor biology, behavior, and potential treatment vulnerabilities.
Does the program focus on one cancer type or multiple cancer types?
The centers are expected to focus on multiple cancer types.
What kinds of outputs does the FOA emphasize?
The FOA emphasizes producing reusable resources for the broader community, including high-value datasets, analytical resources, analytical methods, and curated results that other investigators can apply to their own studies.
Is data sharing an expected component of the program?
Yes. A major goal is to widely share high-value datasets and analytical resources with the broader scientific community to accelerate research and enable reuse.
How does this program support clinically relevant or translational goals?
The FOA highlights a translational goal of applying proteomic and proteogenomic strategies to clinically relevant questions, including improving the ability to predict which treatments are likely to work for a given patient's tumor. This points toward analyses linking molecular profiles to therapeutic response, resistance mechanisms, and clinically meaningful tumor subtypes.
Why combine protein-level data with genomic information?
The FOA frames the rationale as follows: protein-level data, when combined with genomic information, can reveal functional pathway activation and actionable biology that may not be obvious from DNA or RNA data alone. This can improve interpretation of tumor mechanisms and potentially inform precision oncology decisions.
What role does NCI play in a U24 cooperative agreement for this FOA?
Because the awards are U24 cooperative agreements, the FOA indicates awardees will work in close coordination with NCI and the broader CPTAC network, reflecting a collaborative, consortium-based approach rather than isolated projects.
How is this opportunity categorized administratively?
It is categorized as a discretionary grant using the cooperative agreement funding instrument, under the broad activity areas of education and health.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.393, 93.394, and 93.396.
Who is eligible to apply?
The eligible applicant pool is broad and includes: state, county, and local governments; tribal governments and tribal organizations; public housing authorities; independent school districts; public and private institutions of higher education; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses and other for-profits); and other entities as allowed under the announcement's additional eligibility guidance.
Is this opportunity limited to universities or nonprofits?
No. The eligibility list includes many organization types, including public and private higher education institutions, nonprofits, governments, tribal entities, and for-profit organizations (including small businesses).
How many awards were anticipated?
The FOA anticipated making about four awards.
What was the award ceiling for this opportunity?
The award ceiling was $675,000.
When was this opportunity posted and created?
It was posted and created on November 2, 2015.
What was the application closing date?
The application closing date was January 27, 2016.
What is the overall "big picture" goal of this FOA within CPTAC?
Overall, it is an infrastructure-and-analysis focused component of CPTAC aimed at building robust proteogenomic analytical capacity, producing standardized and shareable research outputs, and accelerating community access to data and tools that deepen understanding of cancer biology while supporting clinically oriented discovery.
Browse more opportunities from the same category: Education, Health
Next opportunity: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)
Previous opportunity: Chattahoochee River PLC Trail Crew
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 15 023
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 15 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Systems Biology Approaches in HIV/AIDS and Substance Use (R01) Apply for RFA DA 16 013 Funding Number: RFA DA 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Specialized Genomic Data Center (U24) Apply for RFA CA 15 020 Funding Number: RFA CA 15 020 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $330,000 |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 16 009 Funding Number: PAR 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01) Apply for PAR 16 058 Funding Number: PAR 16 058 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R21) Apply for PA 16 011 Funding Number: PA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Image-guided Drug Delivery (R01) Apply for PAR 16 044 Funding Number: PAR 16 044 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Promoting Caregiver Health Using Self-Management (R01) Apply for RFA NR 16 003 Funding Number: RFA NR 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $350,000 |
| Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) Apply for RFA CA 16 003 Funding Number: RFA CA 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Mechanism for Time-Sensitive Drug Abuse Research (R21) Apply for PAR 16 055 Funding Number: PAR 16 055 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Small Cell Lung Cancer (SCLC) Consortium: Coordinating Center (U24 ) Apply for PAR 16 050 Funding Number: PAR 16 050 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 16 002 Funding Number: RFA CA 16 002 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) Apply for RFA CA 16 004 Funding Number: RFA CA 16 004 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01) Apply for PAR 16 049 Funding Number: PAR 16 049 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Genomic Data Analysis Network: Processing Genomic Data Center (U24) Apply for RFA CA 15 018 Funding Number: RFA CA 15 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Apply for RFA NS 16 013 Funding Number: RFA NS 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01) Apply for PAR 16 051 Funding Number: PAR 16 051 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R01) Apply for PA 16 012 Funding Number: PA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) Apply for PA 16 035 Funding Number: PA 16 035 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 15 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.